Abstract:OBJECTIVETo investigate the imunogenicity and protective efficacy of the divalent DNA vaccine encoding the antigens MPT83 and MPT64 of Mycobacterium tuberculosis.METHODSTwo genes of the M. tuberculosis, MPT83 and MPT64, were amplified and cloned into the vector pJW4303. The vector containing the fusion gene DNA-MM and pJW4303 blank vector were transfected into CO57 cells. The expression of DNA-MM in the supernatant was detected by Western blotting. Thirty-six C57BL/6 mice were divided into 3 equal groups to be injected subcutaneously with the vector containing the fusion gene DNA-MM, pJW4303 blank vector, or bacillus of Calmette-Guerin vaccine (BCG) once a week for 3 weeks. Twelve mice were used as non-immunized controls. Blood samples were collected from the mice before and after every immunization to detect the titer of antibody by ELISA. Three weeks after the 3rd immunization 3 mice from each were killed and their spleens were taken out. The splenocytes were cultured and stimulated by the recombinant antigen to detect the concentrations of interferon (IFN)-gamma and interleukin (IL)-4. Six weeks after the 3rd immunization M. tuberculosis of the line H37Rv was injected intravenously into the mice. Eight weeks later, the mice were killed and their lungs and spleens were taken out. The tissues were cultured to calculate the numbers of M. tuberculosis.RESULTSWestern blotting showed that the CO57 cells transfected with the vector containing the fusion gene expressed DNA-MM. ELISA showed that no antibody titer was detected before immunization in every group. The titer of MPT83 and MPT64 were increased to 1:200, 1:800, and 1:6400 3 weeks after the 1st, 2nd, and 3rd immunization respectively in the divalent group, increased to 1:800 3 weeks after the 3rd immunization in the BCG group, and remained 0 at any time points in the blank vector group. The IFN-gamma titer of the divalent group was 7520 pg/ml, significantly higher than that of the BCG group (6675.6 pg/ml, P < 0.05). The IL-4 concentration was basically the same and at the ng level in all groups. After challenge of H37Rv the bacterial loading in the lung was (2.21 +/- 0.032) x 10(5) in the divalent group, one thousandth of that in the blank vector group, and one tenth of that in the BCG group.CONCLUSIONThe divalent vaccine containing the antigens MPT83 and MPT64 effectively heightens the protective efficiency of vaccine against tuberculosis.

C-terminal heat shock protein 70 of Mycobacterium tuberculosis as a molecular adjuvant for DNA vaccination with the porcine circovirus type 2 ORF2 (capsid) gene in mice

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

Cpg7909 Adjuvant Enhanced Immunogenicity Efficacy In Mice Immunized With Esat6-Ag85a Fusion Protein, But Does Not Confer Significant Protection Against Mycobacterium Tuberculosis Infection

TBK-1 Enhances Humoral and Cellular Immune Responses in Mice Induced by DNA Vaccination of HBV Core Gene

Evaluation of the Enhancing Ability of Three Adjuvants for DNA Vaccination Using the Porcine Circovirus Type 2 ORF2 (capsid) Gene in Mice

A Heterologous DNA Priming-Mycobacterium Bovis BCG Boosting Immunization Strategy Using Mycobacterial Hsp70, Hsp65, and Apa Antigens Improves Protection Against Tuberculosis in Mice.

Protection of Mice with a Divalent Tuberculosis DNA Vaccine Encoding Antigens Ag85B and MPT64

Immunogenicity of porcine circovirus type 2 nucleic acid vaccine containing CpG motif for mice

Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice.

The Truncated Form of Flagellin (tflic) Provides the 2dcap Subunit Vaccine with Better Immunogenicity and Protective Effects in Mice

Study on Immunogenicity and Protective Efficacy of Tetravalent Combination M-Tuberculosis Dna Vaccinea

[Immunogenicity and Protection of Divalent DNA Vaccine Encoding Antigens MPT83 and MPT64 of Mycobacterium Tuberculosis].

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

Nanoparticle-based Adjuvant for Enhanced Protective Efficacy of DNA Vaccine Ag85A-ESAT-6-IL-21 Against Mycobacterium Tuberculosis Infection.

Surface Display of porcine circovirus type 2 antigen protein cap on the spores of bacillus subtilis 168: An effective mucosal vaccine candidate

Improved Humoral Immunity Against Tuberculosis Esat-6 Antigen By Chimeric Dna Prime And Protein Boost Strategy

Induction Of Specific Humoral And Cellular Immune Responses In A Mouse Model Following Gene Fusion Of Hsp70c And Hantaan Virus Gn And S0.7 In An Adenoviral Vector

Co-expression of Ubiquitin Gene and Capsid Protein Gene Enhances the Potency of DNA Immunization of PCV2 in Mice

Immunoenhancement of recombinant Neisseria meningitides PorB protein on porcine circovirus type 2 and Mycoplasma hyopneumo-niae genetically engineered vaccines.

Humoral and Cellular Immune Responses Induced by Bivalent DNA Vaccines Expressing Fusion Capsid Proteins of Porcine Circovirus Genotypes 2a and 2b

The cellular immune response and protective efficacy against tuberculosis infection of a novel mycobacterium tuberculosis DNA vaccine p846